Green bio and molecular diagnostics specialist company Genolution announced on the 12th that it signed a strategic business agreement (MOU) with the diagnostics and genomics division (Biosearch Technologies) of British global life science company LGC on the 11th.
Through this agreement, the two companies plan to apply LGC's next-generation nucleic acid purification chemistry technology, sbeadex™ Lightning, to Genolution's automation platform Nextractor® NX-Duo and related kit solutions, and pursue joint business targeting global markets such as Asia Pacific, Europe, the Middle East, Canada, and Central and South America.
The agreement is a strategic partnership aimed at providing high-efficiency, high-purity nucleic acid purification solutions for agricultural genomics research institutes and molecular breeding researchers. By combining LGC's magnetic bead-based technology with the automation capabilities of the Genolution platform, it is expected to enable high-throughput and high-purity nucleic acid acquisition.
LGC is a global life sciences company with over 180 years of history and operations in 14 countries. As of 2024, it had approximately KRW 1.34 trillion in sales and 3,800 employees, of which more than 1,100 hold master's degrees or higher.
“By combining our innovative sbeadex™ Lightning technology with Genolution’s automated platform, we have created an intuitive and fast nucleic acid purification system,” said Thomas Winkelmüller, Product Manager for LGC’s Diagnostics & Genomics business unit. “This will enable molecular breeding and plant researchers to obtain high-quality DNA in less time.”
A Genolution representative said, “Through this agreement, we will be able to expand the performance and scope of use of the NX-Duo platform,” and “By combining the technological strengths of both companies, we will provide solutions optimized for the demands of the agricultural genomics field.”
Meanwhile, Genolution's NX-Duo platform, an automated device with flexible processing modes and a user-friendly interface, will be upgraded through this agreement to a kit solution supporting LGC's sbeadex™ Lightning protocol. Genolution plans to begin field validation and commercialization of the solution in earnest in the second half of 2025.
This collaboration is seen as reflecting the two companies' joint strategy to simultaneously secure technological reliability, scalability, and quality in the field of agricultural genome research.
- See more related articles
You must be logged in to post a comment.